IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares gapped down before the market opened on Tuesday . The stock had previously closed at $46.75, but opened at $43.61. IPSEN shares last traded at $43.61, with a volume of 300 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on IPSEY shares. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Finally, HC Wainwright started coverage on IPSEN in a research note on Friday, June 5th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

IPSEN Stock Performance

The stock’s 50 day moving average is $47.94 and its 200 day moving average is $43.13.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).